Results 231 to 240 of about 144,544 (285)
Editorial: Extracellular vesicles in cancer research: a new era for therapeutic interventions. [PDF]
Singh T.
europepmc +1 more source
As the breakthrough bispecific antibody targeting EGFR and c‐Met, EMB‐01 drives potent anti‐tumor efficacy by co‐degradation of both receptors. ABSTRACT The bispecific antibody EMB‐01 (bafisontamab), constructed using EpimAb's proprietary FIT‐Ig platform, is designed to simultaneously target epidermal growth factor receptor (EGFR) and receptor tyrosine
Jing Gao +9 more
wiley +1 more source
Long-tailed class I myosins rely on tail-mediated phosphoinositide recognition for specific membrane recruitment. [PDF]
Rajendraprasad G +8 more
europepmc +1 more source
PIK‐III enhancing the efficacy of cuproptosis to kill renal cancer cells through dysregulating thiamine metabolism and dephosphorylation of pyruvate dehydrogenase complex E1 (PDHA1), providing a potential option for treatment of cuproptosis‐resistant renal cancer by the combination of PIK‐III and elesclomol.
Dongdong Xie +8 more
wiley +1 more source
SNX16 aggravates AngII-induced cardiac hypertrophy in mice via EGFR transactivation. [PDF]
Xie L +17 more
europepmc +1 more source
LMPt enters the cell mainly through caveolin‐mediated endocytosis, and then fuses with endosomes and lysosomes to deliver MPt to mitochondria and the endoplasmic reticulum to induce mitophagy based on the fusion of lysosomes and mitochondria, and endoplasmic reticulum stress and subsequent apoptosis via the Bip–PERK–eIF2α–ATF4 axis to exert an anti ...
Cong Zhao +9 more
wiley +1 more source
ESCRTing the RABs through conversion. [PDF]
Solinger JA, Ott DP, Spang A.
europepmc +1 more source
Insights Into Macrophage Ferroptosis: Implications for Atherosclerosis
Macrophage ferroptosis drives atherosclerosis by enhancing oxidative stress and inflammation, accelerating plaque progression and instability. Targeting macrophage ferroptosis presents a promising therapeutic strategy for atherosclerosis treatment.
Xiehui Chen, Xiangbo Liu, Changchun Zeng
wiley +1 more source

